Genetic engineering recombinant strain for producing tetracycline as well as construction method and application of genetic engineering recombinant strain
By introducing genes of the tetracycline biosynthesis pathway into the oleracin synthesis pathway, a genetically engineered recombinant strain that efficiently produces tetracycline was constructed, which solved the problems of genetic operation difficulties of Streptomyces aureus and the unimproved tetracycline fermentation level, and achieved high efficiency and low tetracycline Cost production.
Patent Information
- Application Number
- CN202310561708.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-22
AI Technical Summary
The genetic operation of Streptomyces aureus in the prior art has caused no significant improvement in the fermentation level of tetracycline, and there are few reports in the literature, making it difficult to improve the production efficiency of tetracycline.
By introducing the tetracycline synthesis-related genes C6, C5 hydroxylase and C5a-C11a reductase from the tetracycline biosynthesis pathway to the tetracycline synthesis pathway for in situ or ectopic replacement, a gene capable of efficient production of tetracycline was constructed. Engineering recombinant strains.
The improvement of tetracycline fermentation level has been achieved, providing efficient and low-cost industrial production solutions, and can be used to produce tetracycline and its analogues, such as demethyltetracycline and ceromycin.
Smart Images

Figure BDA0004235225190000091 
Figure HDA0004235225210000011 
Figure HDA0004235225210000012
Abstract
Description
Technical Field
[0001] The invention relates to the field of genetic engineering or molecular biology, and in particular to a genetic engineering recombinant strain for producing tetracycline, a construction method and application thereof. Background Art
[0002] Tetracycline antibiotics are a class of broad-spectrum antibiotics produced by Streptomyces. Naturally isolated ones include chlortetracycline (CTC), oxytetracycline (OTC), tetracycline (TC), and demethylchlortetracycline (6-DCT); semi-synthetic tetracycline derivatives include methacycline (methacycline), doxycycline (doxycycline or deoxytetracycline), minocycline (minocycline), and tigecycline (tigecycline).
[0003] Tetracycline is mainly produced by fermentation of Streptomyces aureofacines. Due to the difficulty of genetic manipulation of Streptomyces aureofacines, breeding is limited to conventional mutagenesis breeding in this strain, resulting in no significant improvement in tetracycline fermentation levels for many years, and few literature reports. Summary of the invention
[0004] The purpose of the present invention is to provide a genetically engineered recombinant strain for producing tetracycline and a construction method and application thereof.
[0005] To achieve the above purpose, the present invention adopts the following technical solution:
[0006] A genetically engineered recombinant strain for producing tetracycline, wherein the oxytetracycline synthesis-related gene C6, C5 hydroxylase and / or oxytetracycline synthesis-related gene C5a-C11a reductase in the starting strain are replaced in situ or ectopically; the starting strain is a strain capable of biosynthesizing oxytetracycline.
[0007] The recombinant strain is a starting strain in which the oxytetracycline synthesis-related genes C6 and C5 hydroxylase are replaced in situ or ectopically by C6 hydroxylase from the tetracycline biosynthesis pathway; and / or the oxytetracycline synthesis-related gene C5a-C11a reductase in the starting strain is replaced in situ or ectopically by C5a-C11a reductase from the tetracycline biosynthesis pathway.
[0008] The strain capable of biosynthesizing oxytetracycline is Streptomyces rimosus, S. rimosus LS-TI 18 (Russian), S. rimosus M4018 (Pfizer) or S. rimosus R6 (Zagreb), etc., preferably Streptomyces rimosus.
[0009] The strain having a tetracycline biosynthesis pathway is Streptomyces aureofaciens, Streptomyce viridofaciens, Streptomyces sp. SF2575 or Dactylosporangium sp. SC14051, etc., preferably Streptomyces aureofaciens.
[0010] The recombinant strain is a starting strain in which the oxytetracycline synthesis-related genes C6 and C5 hydroxylase are replaced in situ or ectopically by C6 hydroxylase from the tetracycline biosynthesis pathway; and / or the oxytetracycline synthesis-related gene C5a-C11a reductase in the starting strain is replaced in situ or ectopically by C5a-C11a reductase from the tetracycline biosynthesis pathway.
[0011] Specifically:
[0012] The tetracycline C6 hydroxylase gene is ctcN, and the tetracycline C5a-C11a reductase gene is ctcM.
[0013] The oxytetracycline synthesis-related genes C6, C5 hydroxylase oxyS, and C5a-C11a reductase oxyR are replaced in situ by the tetracycline C6 hydroxylase gene ctcN and the tetracycline C5a-C11a reductase gene ctcM respectively or simultaneously.
[0014] Further,
[0015] The C5a-C11a reductase gene ctcM replaces the oxytetracycline synthesis-related gene C5a-C11a reductase oxyR in situ to obtain a genetically engineered recombinant strain producing tetracycline.
[0016] The C6 hydroxylase gene ctcN replaces the oxytetracycline synthesis-related genes C6 and C5 hydroxylase oxyS in situ to obtain a genetically engineered recombinant strain producing tetracycline.
[0017] The C6 hydroxylase gene ctcN and the C5a-C11a reductase gene ctcM simultaneously replace in situ the oxytetracycline synthesis-related genes C6, C5 hydroxylase oxyS and C5a-C11a reductase oxyR to obtain a genetically engineered recombinant strain producing tetracycline.
[0018] The base sequence of the C6 hydroxylase from the tetracycline biosynthetic pathway is shown by the bases in SEQ ID NO: 1; or a sequence having at least 30% amino acid sequence homology thereto.
[0019] The base sequence of the C5a-C11a reductase from the tetracycline biosynthetic pathway is shown by the bases in SEQ ID NO: 2; or a sequence having at least 30% amino acid sequence homology thereto.
[0020] A method for constructing a genetically engineered recombinant strain for producing tetracycline utilizes DNA homologous recombination to replace C6 and C5 hydroxylases in a strain capable of biosynthesizing oxytetracycline in situ or ectopic position, thereby obtaining a recombinant strain for producing tetracycline.
[0021] Specifically, DNA homologous recombination is used to replace the functional genes ctcM and / or ctcN in the tetracycline biosynthesis gene cluster in situ or ectopically with the functional genes oxyR and / or oxyS in the oxytetracycline biosynthesis gene cluster in the strain having oxytetracycline biosynthesis, thereby obtaining a recombinant strain that produces tetracycline.
[0022] An application of the genetically engineered recombinant strain for producing tetracycline, and an application of the recombinant strain in producing tetracycline or its analogs.
[0023] A method for producing tetracycline or its analogs comprises the steps of shaking and culturing the recombinant strain at 30-35°C, collecting the fermentation liquid, and purifying the mixture to produce tetracycline or its analogs.
[0024] Specifically, the method comprises using the recombinant Streptomyces of the present invention or the recombinant Streptomyces obtained by the method for producing the recombinant Streptomyces of the present invention, and optionally comprises recovering and purifying the produced tetracycline.
[0025] In one embodiment, the present invention provides a method for producing tetracycline, comprising: culturing the recombinant Streptomyces of the present invention or the recombinant Streptomyces obtained by the method of the present invention under conditions suitable for tetracycline production, harvesting the produced tetracycline, and optionally isolating or purifying it.
[0026] In one embodiment, the present invention provides a method for producing tetracycline, comprising: carrying out seed culture of the recombinant Streptomyces of the present invention or the recombinant Streptomyces obtained by the method of the present invention, then inoculating a fermentation medium and fermenting under conditions suitable for the production of tetracycline, harvesting the fermentation broth, and optionally separating and / or purifying the produced tetracycline.
[0027] The seed culture and fermentation culture of the present invention can use any suitable method, conditions and materials known in the art. The seed culture medium and fermentation culture medium can use any suitable culture medium known in the art. The purification method can be carried out using any suitable method and technology known in the art, such as but not limited to chromatographic extraction, crystallization, resin adsorption, ion exchange adsorption, chromatography and HPLC.
[0028] By replacing one or more genes in situ or ectopic, the strain that synthesizes oxytetracycline is transformed into a strain that synthesizes tetracycline, providing excellent genetically engineered strains for the efficient and low-cost industrial production of tetracycline antibiotics.
[0029] More specifically, the frozen strain at -80°C was inoculated on an eggplant-shaped flask slant medium (8% bran, 2.5% agar, the balance being water, sterilized) at 37°C for 64-72h, transferred to 28-35°C for further culturing for 3-5d, and then the spores were scraped and inoculated into a seed medium (2% corn starch, 0.5% soybean meal, 0.7% yeast powder, 0.1% corn steep liquor, 0.5% NaCl, 0.3% CaCO3, the balance being water, the pH value was adjusted to 7.2, sterilized), cultivated at 28-35°C and 250rpm for 24-36h as primary seeds, and then inoculated into secondary seed medium (the same primary seeds in the formula) at an inoculum amount of 10wt%, cultivated at 28-35°C and 250rpm for 24-30h as secondary seeds, and then inoculated into a fermentation medium (8% corn starch, 3% soybean meal, 1% corn steep liquor, NaCl) at an inoculum amount of 10wt%. 0.5%, CaCO3 0.8%, KH2PO4 0.05%, (NH4)2SO4 0.08%, MgSO4 0.6%, the balance is water; adjust the pH value to 7.2 and sterilize), culture at 30-35℃ 250rpm for 5-8d, collect the fermentation broth, filter on plate and frame, collect the bacteria and dry them into powder, and finally extract and purify tetracycline or its analogues according to different uses.
[0030] As used herein, a gene encoding a specific amino acid sequence refers to a gene that generates a protein having the amino acid sequence when expressed in an appropriate organism (e.g., streptomyces producing oxytetracycline, particularly streptomyces oxytetracycline). The gene includes a coding sequence encoding the amino acid sequence, and may also include a regulatory sequence that regulates the expression of the gene, such as a promoter, etc. For example, the genes ctcN and ctcM encoding the sequences shown in SEQ ID NO: 1 and SEQ ID NO: 2 refer to genes that produce an amino acid sequence with a specific activity when expressed in streptomyces, such as streptomyces oxytetracycline, which is referred to as a protein or enzyme; in the present invention, the ctcN and ctcM genes not only encompass the nucleotide sequences encoding SEQ ID NO: 1 and SEQ ID NO: 2, but also encompass regulatory sequences that regulate their expression, such as promoters, etc.
[0031] The advantages of the present invention are:
[0032] The present invention utilizes the in situ replacement plasmid of homologous arms, which is introduced into oxytetracycline-producing bacteria by conjugation transfer, and accurately replaces the target gene in the oxytetracycline-producing bacteria with the exogenous target gene in situ, transforming the strain that synthesizes oxytetracycline to directly synthesize tetracycline. Finally, the genetically engineered recombinant strain no longer synthesizes oxytetracycline, but starts to synthesize tetracycline.
[0033] The method of the present invention can arbitrarily transform oxytetracycline production strains to obtain tetracycline genetic engineering bacteria with higher fermentation levels, thereby providing excellent strains for the industrial production of tetracycline.
[0034] The method of the present invention is easier to genetically manipulate using oxytetracycline production strains, and the tetracycline fermentation level is higher than the fermentation level of oxytetracycline of the original strain before transformation. It can be used for efficient synthesis and industrial production of tetracycline, and a series of biosynthetic tetracycline analogs such as demethyltetracycline, chlortetracycline, demethylchlortetracycline and other genetically engineered high-yield strains can be obtained after further transformation. The technical method and recombinant engineering strain involved in the present invention have important application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 The molecular structural formulas of oxytetracycline (OTC) and tetracycline (TC) provided in the embodiments of the present invention.
[0036] Figure 2 Electrophoretic diagrams of PCR screening and verification of gene replacement strains provided in an embodiment of the present invention, wherein A: PCR verification of ctcM replacing oxyR mutant strain OT102; B: PCR verification of ctcN replacing oxyS mutant strain OT103; C: PCR verification of ctcM and ctcN simultaneously replacing oxyR and oxyS mutant strain OT104;
[0037] Figure 3 This is an HPLC detection profile of the fermentation product of the strain provided in the embodiment of the present invention, wherein A: tetracycline standard; B: original strain fermentation sample; C: genetically engineered recombinant strain OT104 fermentation sample (ie, double substitution).
[0038] Figure 4 This is a mass spectrometry diagram of a fermentation sample of a genetically engineered double-substituted recombinant strain provided in an embodiment of the present invention. DETAILED DESCRIPTION
[0039] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0040] The present invention constructs an in situ replacement plasmid containing homologous arms, introduces it into the oxytetracycline-producing bacteria OT101 by conjugation transfer, and utilizes the principle of homologous recombination of Streptomyces to accurately replace the target gene in the oxytetracycline-producing bacteria with the exogenous target gene in situ, and finally the genetically engineered recombinant strain no longer synthesizes oxytetracycline but starts to synthesize tetracycline.
[0041] Those skilled in the art can refer to the content of this article and appropriately change the exogenous gene part DNA to achieve the synthesis of tetracycline by recombinant bacteria. It should be particularly noted that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0042] Herein, the original strain refers to Streptomyces existing in the natural environment without any artificial manipulation.
[0043] In the present invention, the original strain for producing the recombinant Streptomyces refers to the Streptomyces to which the genetic manipulations shown in the present invention, such as gene inactivation and gene replacement, are performed. The original strain can be a wild-type Streptomyces producing oxytetracycline, or a Streptomyces for producing oxytetracycline with other genetic modifications but without the genetic modification described in the present invention.
[0044] As used herein, "recombinant" refers to a strain with desired modifications obtained due to intentional human intervention, for example, compared with the corresponding natural (non-recombinant) strain, the recombinant strain expresses a specific natural gene or its activity that is absent or not expressed or is expressed at a low level.
[0045] In the present invention, the term "replacement" includes partial or complete inactivation of the original gene, while the foreign gene partially or completely replaces the original gene to play a special function. Replacement can be achieved by, for example, targeting vectors, replacement vectors or hit-and-run vectors, homologous recombination, or random insertion of gene trap vectors to cause heterologous expression and function of the foreign target gene.
[0046] The experimental methods in the following examples, for which specific conditions are not specified, are generally carried out under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by weight. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention. The preferred embodiments and materials described herein are for exemplary purposes only.
[0047] Example 1: Extraction of Streptomyces genomic DNA
[0048] Take 50 μL of frozen tube spore suspension of oxytetracycline-producing bacteria Streptomyces rimosus OT101 and tetracycline-producing bacteria Streptomyces aureofaciens CT101 and inoculate them into 30 mL TSB medium (purchased from Bacto Tryptic Soy Broth. BD Company) respectively, culture at 28°C and 220 rpm for 48 hours, centrifuge at 4000 rpm for 10 minutes in a 50 mL centrifuge tube, remove the supernatant, wash the precipitate twice with 30 mL sucrose-Tris buffer (wherein the mass percentage of sucrose is 10.3%, the molar-volume concentration of Tris-HCl is 10 mM, and the pH value is 8.0), and suspend it with 5 mL sucrose-Tris buffer. After suspension, add 20 μL of lysozyme solution with a mass-volume solubility of 100 mg / mL, and water bath at 37°C for 2 hours. After water bathing, add 500 μL of SDS solution with a mass percentage of 10%, and gently invert until it is basically clear. After the system is clarified, 5 mL of phenol-chloroform-isoamyl alcohol (wherein: the volume ratio of phenol-chloroform-isoamyl alcohol is 25:24:1 (pH value is 8.0) solution is added, and after gentle inversion several times, centrifugation is carried out at 4000 rpm for 10 min. Take 4 mL of the upper solution, add 4 mL of phenol-chloroform-isoamyl alcohol (pH value is 8.0) solution, gently invert several times, and centrifuge at 4000 rpm for 10 min. Then take 3 mL of the upper solution, add 300 μL of NaAc buffer (pH value is 5.3) with a molar-volume concentration of 3 mol / L and 3 mL of isopropanol, and after gentle inversion several times, the clumped precipitate is picked into a new 1.5 mL centrifuge tube. The precipitate is washed twice with a volume fraction of 70% ethanol aqueous solution and dried at room temperature. 500 μL of Tris-HCl (pH 8.0) is added to dissolve, and the genomic DNA of oxytetracycline-producing bacteria and tetracycline-producing bacteria are obtained respectively.
[0049] Example 2: Construction of a recombinant vector in which the gene ctcM replaces oxyR in situ
[0050] The genome of oxytetracycline-producing bacterium OT101 was used as a template and primers PCT01F (tgcaggtcgactctagagCCCAAAGCC ACCCGGTCATCCT) and PCT01R (tcgagctcggtacccggg aggcctThe upstream fragment of oxyR was amplified by PCR. The total system of PCR reaction was 40 μL, including 2×GCIBuffer 20 μL, dNTP 4 μL, Streptomyces rimosus OT101 genomic DNA 1 μL, primer PCT01F and primer PCT01R 1 μL each, PrimerSTAR DNA polymerase 1 μL, water 14 μL. The reaction conditions were: 95℃2min; 98℃15s, 62℃15s, 72℃2min, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 2049 bp was recovered using the gel recovery kit. The suicide vector pTA1 (the complete coding frame of the thiostrepton resistance gene Thio was cloned at the KpnI site of the Streptomyces gene knockout universal vector pOJ260 to obtain a new vector pTA1 with functional elements such as Thio resistance gene, Apra resistance gene, and oriT) was cut with BamHI, and the two fragments were assembled with Gibson enzyme to obtain the intermediate vector pTA02.
[0051] Then, using the OT101 genome as a template, primer PCT02F (attcgggcagttccc aggcct The downstream fragment of oxyR was amplified by using the primers PCT02F (GAAGCGTCCTCGGGGTCCGTAG) and PCT02R (agctcggtacccgggag gTA GTGCTTGCGGGCGTGCTGGA). The total system of PCR reaction was 40μL, including 2×GCI Buffer 20μL, dNTP 4μL, Streptomycesrimosus OT101 genomic DNA 1μL, primer PCT02F and primer PCT02R 1μL each, PrimerSTAR DNA polymerase 1μL, and water 14μL. The reaction conditions were: 95℃2min; 98℃15s, 60℃15s, 72℃2min, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 2059bp was recovered using the gel recovery kit. The intermediate vector pTA02 was digested with StuI, and the two fragments were assembled with Gibson enzyme to obtain the intermediate vector pTA03.
[0052] The genome of tetracycline-producing bacteria Streptomyces aureofaciens CT101 was used as a template to amplify ctcM gene CDS 423bp using primers PCT03F (gaaattcgggcagttcccTCATGCCTGCGCCCCCGCCCCG) and PCT03R (ggaccccgaggacgcttcATGCCATTCACCGCGAAAGAGG). The total system of PCR reaction was 40μL, including 2×GCI Buffer 20μL, dNTP 4μL, Streptomyces aureofaciens CT101 genomic DNA 1μL, primers PCT03F and PCT03R 1μL each, PrimerSTAR DNA polymerase 1μL, and water 14μL. The reaction conditions were: 95℃2min; 98℃15s, 60℃15s, 72℃30s, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 423 bp was recovered using a gel recovery kit. The intermediate vector pTA03 was digested with StuI, and the two fragments were assembled with Gibson enzyme to obtain the final vector pTA04.
[0053] Example 3: Construction of a recombinant vector in which the gene ctcN replaces oxyS in situ
[0054] The genome of oxytetracycline-producing bacterium OT101 was used as a template and primers PCT05F (tgcaggtcgactctagagCGCCGTCGC CGAGGAAAGGTT) and PCT05 (tcgagctcggtacccggg aggcct ACACGCTCCTCGGATC ATCAGT) PCR amplified the upstream fragment of oxyS. The total system of PCR reaction was 40μL, including 2×GCI Buffer 20μL, dNTP 4μL, Streptomyces rimosus OT101 genomic DNA 1μL, primer PCT05F and primer PCT05R 1μL each, PrimerSTAR DNA polymerase 1μL, water 14μL. The reaction conditions were: 95℃2min; 98℃15s, 62℃15s, 72℃2min, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 2149bp was recovered using a gel recovery kit. The suicide vector pTA1 was digested with BamHI, and the two fragments were assembled with Gibson enzyme to obtain the intermediate vector pTA05.
[0055] Then, using the OT101 genome as a template, primer PCT06F (atccgaggagcgtgt aggcctThe total system of PCR reaction was 40μL, including 2×GCI Buffer 20μL, dNTP 4μL, Streptomycesrimosus OT101 genomic DNA 1μL, primer PCT06F and primer PCT06R 1μL each, PrimerSTAR DNA polymerase 1μL, water 14μL. The reaction conditions were: 95℃2min; 98℃15s, 62℃15s, 72℃2min, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 2060bp was recovered using a gel recovery kit. The intermediate vector pTA05 was digested with StuI, and the two fragments were assembled with Gibson enzyme to obtain the intermediate vector pTA06.
[0056] Using the genome of tetracycline-producing bacteria CT101 as a template, primers PCT07F (tgatgatccgaggagcgtgtTTGGACTG CGATGTGGTGGTGG) and PCT07R (gggaaccgggtgggggtgccTCAGGCCGCCGCGCCGAAC CAG) were used to amplify ctcN gene CDS 1473bp by PCR. The total system of PCR reaction was 40μL, including 2×GCI Buffer 20μL, dNTP 4μL, Streptomyces aureofaciens CT101 genomic DNA 1μL, primers PCT03F and PCT03R 1μL each, PrimerSTAR DNA polymerase 1μL, and water 14μL. The reaction conditions were: 95℃2min; 98℃15s, 60℃15s, 72℃1.5min, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 1473 bp was recovered using a gel recovery kit. The intermediate vector pTA06 was digested with StuI, and the two fragments were assembled with Gibson enzyme to obtain the final vector pTA07.
[0057] Example 4: Construction of a recombinant vector in which the genes ctcM / ctcN simultaneously replace oxyR / oxyS in situ
[0058] oxyR upstream fragment PCR and intermediate vector pTA02 construction reference example 2. Using the genome of oxytetracycline producing bacteria OT101 as a template, primers PCT09F (attcgggcagttccc aggcctGGCACCCCCACCCGGTTCCCTG) and PCT06R were used to amplify the downstream fragment of oxyS. The total system of PCR reaction was 40μL, including 2×GCI Buffer 20μL, dNTP 4μL, Streptomyces rimosus OT101 genomic DNA 1μL, primer PCT09F and primer PCT06R 1μL each, PrimerSTAR DNA polymerase 1μL, and water 14μL. The reaction conditions were: 95℃2min; 98℃15s, 62℃15s, 72℃2min, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 2060bp was recovered using a gel recovery kit. The intermediate vector pTA02 was digested with StuI, and the two fragments were assembled with Gibson enzyme to obtain the intermediate vector pTA08.
[0059] The genome of tetracycline-producing bacteria CT101 was used as a template, and primers PCT03F and PCT07R were used to amplify the complete CDS of ctcM / ctcN genes of 2060 bp. The total system of PCR reaction was 40 μL, including 2×GCI Buffer 20 μL, dNTP 4 μL, Streptomyces aureofaciens CT101 genomic DNA 1 μL, primer PCT03F and primer PCT07R 1 μL each, PrimerSTAR DNA polymerase 1 μL, and water 14 μL. The reaction conditions were: 95℃2min; 98℃15s, 60℃15s, 72℃2min, 30cycles; 72℃10min. After the PCR product was loaded on the electrophoresis, the target band of 2060 bp was recovered using a gel recovery kit. The intermediate vector pTA08 was digested with StuI, and the two fragments were assembled with Gibson enzyme to obtain the final vector pTA09.
[0060] Example 5: Obtaining recombinant Streptomyces by in situ gene replacement
[0061] The recombinant vectors constructed in Examples 2, 3, and 4, i.e., vector pTA04, vector pTA07, and vector pTA09, were introduced into Escherichia coli ET12567 (pUZ8002), respectively, and then introduced into Streptomyces OT101 by the conjugation transfer method (reference Kieser T, Bibb M. Practical Streptomyces Genetics [M]. Norwich: The John Innes Foundation, 2000), respectively, to obtain a single exchanger resistant to thiostrepton (Thio). After two consecutive generations on an MS plate without antibiotics, single colonies were picked and seeded on plates with (the final concentration of Thio added was 25 ug / ml) and without Thio, and cultured at 32°C for 8 days. The single colony that lost Thio resistance was selected, i.e., the recombinant strain obtained, and the genomic DNA was extracted and PCR amplification was performed using the corresponding primers for verification. The specific verification process is as follows:
[0062] (1) OT101 / pTA04 double exchanger verification: using primers
[0063] PCT04F(GACGGCGAGTTGAGCCAGACCA) and
[0064] PCT04R (GTCCCGCTGGGCTTCCACTACA A) was used for PCR amplification verification. The total system of PCR reaction was 20 μL, including 10 μL of 2×GCI Buffer, 1 μL of dNTP, 0.5 μL of Streptomyces aureofaciens CT101 genomic DNA, 0.5 μL of primer PCT04F and primer PCT04R, 0.5 μL of PrimerSTAR DNA polymerase, and 7 μL of water. The reaction conditions were: 95°C for 2 min; 98°C for 15 s, 62°C for 15 s, 72°C for 1 min, 20 cycles; 72°C for 10 min. The PCR products were loaded for electrophoresis. No fragments were produced in the original strain, and the double exchanger, i.e., the strain where oxyR was replaced by ctcM, could amplify a 790 bp fragment (see Figure 2 A);
[0065] (2) OT101 / pTA07 double exchanger verification: using primers
[0066] PCT08F(TACGGCAGCACATCCCAC G) and
[0067] PCT08R (ACTCCTCGAAGCGCATCGGCAC) was used for PCR amplification verification. The total system of PCR reaction was 20 μL, including 10 μL of 2×GCI Buffer, 1 μL of dNTP, 0.5 μL of Streptomyces aureofaciens CT101 genomic DNA, 0.5 μL of primer PCT08F and primer PCT08R, 0.5 μL of PrimerSTAR DNA polymerase, and 7 μL of water. The reaction conditions were: 95°C for 2 min; 98°C for 15 s, 58°C for 15 s, 72°C for 1 min, 20 cycles; 72°C for 10 min. The PCR products were loaded for electrophoresis. No fragments were produced in the original strain, and the double exchanger, i.e., the strain where oxyS was replaced by ctcN, could amplify a fragment of 883 bp (see Figure 2 B);
[0068] (3) Verification of the double exchanger of OT101 / pTA09: PCR amplification was performed using primers PCT04F and PCT04R. No fragments were produced in the original strain, and a 732 bp fragment was amplified in the double exchanger strain, i.e., the strain in which oxyR was replaced by ctcM (see Figure 2 C-1), and at the same time, PCR amplification was performed using primers PCT08F and PCT08R to verify that the original strain did not produce any fragments, and the double exchanger, that is, the strain where oxyS was replaced by ctcN, could amplify a 883bp fragment (see Figure 2 C-2);
[0069] All strains verified as double exchangers by PCR were then amplified with primers PCT04F / PCT10R (TGTGCAGGGCCTTCGCCTGGTGGTA) to amplify the complete sequence of about 2700bp upstream and downstream of the replaced site, and then the amplified fragments were cloned into pMD19T and sequenced separately to further confirm that the recombinant strains had undergone in situ replacement. After dual verification by PCR and sequencing, it was confirmed that the gene recombinant strains with gene replacement at the expected position were obtained.
[0070] Example 6: Fermentation verification of genetically engineered recombinant strains
[0071] The recombinant strains and the original strain (oxytetracycline-producing bacteria OT101) verified by PCR and sequencing were inoculated on eggplant-shaped flask slant medium (8% bran, 2.5% agar, the balance is water, sterilized) at 37°C for 64-72h, transferred to 28-35°C for another 3-5d, and then the spores were scraped and inoculated into seed medium (2% corn starch, 0.5% soybean cake powder, 0.7% yeast powder, 0.1% corn steep liquor, 0.5% NaCl, 0.3% CaCO3, the balance is water, the pH value was adjusted to 7.2, and sterilized), cultured at 28°C and 250rpm for 24-36h as primary seeds, and then inoculated into secondary seed medium (the same first-level seeds in the formula) at an inoculum amount of 10wt%, cultured at 28-35°C and 250rpm for 24-30h as secondary seeds, and then inoculated into fermentation medium (8% corn starch, 3% soybean cake powder, 1% corn steep liquor, NaCl) at an inoculum amount of 10wt%. 0.5%, CaCO3 0.8%, KH2PO4 0.05%, (NH4)2SO40.08%, MgSO4 0.6%, the balance is water; adjust the pH value to 7.2, sterilize), 30-35℃, 250rpm, culture for 5-8 days, collect the fermentation broth, take 1mL of the fermentation broth, soak it with 2mL 2mol HCl for 10 minutes, add 7mL 0.01mol HCl, ultrasonicate for 30min, centrifuge and take the supernatant for HPLC detection. HPLC analysis conditions, chromatographic column: Elite Hypersil ODS2 5μm (4.6*250mm); mobile phase: purified water: 2mol / L phosphoric acid solution: N,N-dimethylformamide = 720:20:260, detection wavelength 365nm, flow rate: 1ml / min, column temperature: 35℃, injection volume 20μL.
[0072] The results of liquid phase detection showed that the strain that originally produced oxytetracycline no longer produced oxytetracycline after in situ single gene replacement or simultaneous replacement of two genes, and a new peak was generated at the same time as the tetracycline peak (see Figure 3 ), the genetically engineered recombinant bacteria can synthesize tetracycline normally, and the fermentation level is up to 30% higher than that of the original strain that synthesizes oxytetracycline (see Table 1).
[0073] Table 1: Strain fermentation data
[0074]
[0075] At the same time, the fermentation broth of the recombinant bacteria was further treated according to the standard, and the target peak was further purified and separated by HPLC liquid phase. After a certain amount was collected, mass spectrometry was performed. The mass spectrometry spectrum showed that the molecular weight of the target peak compound was 444, which was completely consistent with the molecular weight of tetracycline (see Figure 4), while the molecular weight of oxytetracycline is 460. In summary, by utilizing the genetic engineering directed transformation of the present invention and heterologous in situ expression of special functional genes, the oxytetracycline-producing bacteria are transformed into tetracycline-producing bacteria, which can increase the yield by nearly 30%. The method of the present invention can be applied to any oxytetracycline-producing strain, so that the yield of tetracycline and other analogues of the transformed recombinant strain is significantly higher than that of the starting strain. The method of the present invention can provide a better transformation method and excellent production strain for industrial production.
[0076] ctcN base sequence 1473
[0078] DNA
[0079] Streptomyces aureofaciens
[0080] ttggactgcgatgtggtggtggcgggagcggggccgaccggcctgatgctcgcctgcgaa
[0081] ctggccctgggcggagcccgggcggtggtggtggaacggcgccgcgagccggagaagcac
[0082] tccaaggccatgggcatgcagggccgcaccgtggaactgctcgaactgcgcgggctgctc
[0083] gaccgcttcaaggagggcgcgggcgtgctgcagggcggcaacttcgccagcctgggcgtg
[0084] ccgatgcgcttcgaggagttcgacacccgccacccgtacgtgctgctggtgccccaactg
[0085] cgcaccgaggagctgctcgccgaacgggcccgcgaactgggcgtgcggatcgtgcgcggc
[0086] tcgggtgtcaccggcttcgcccaggacgccgacggggtcaccgtagagacggacacgggc
[0087] ccgcttcgggcacggtacctggtcggctgcgacggcggcggcagcaccgtccgcaaggcc
[0088] gccggcatcagcttcaccggacaggacccgcacatgtacgccctcatcggcgacatgcgc
[0089] ttcagcggcgacctgccgcgcggcgagggcctcggcccgatgcggccggtgggcctggtc
[0090] aaccccgccaagcggtcctggttcggcgccttccagcaccagccgggcgtctaccgggcc
[0091] accgtcgcctggttcgaccggcccttcgccgaccgccgcgccccggtcaccgaggaggag
[0092] atgcgcgccgcactggtcgagcacaccggcagtgaccacgggatgcacgacgtcacctgg
[0093] ctgtcccgcctcaccgacgtctcccggctggccgactgctaccggcagggccgggtgctg
[0094] ctggccggcgacgccgcgcacatccacctgccggccggcggccaggggctcaacctgggt
[0095] ttccaggacgccgtcaacctcggctggaagctggccgccgtggtccgcggccacggcacc
[0096] gaggagctgctggacagctacggccgcgagcgtcgcccgatcgccgacggcgtggtgcgc
[0097] aacacccgcacccaggccgtcctgatcgacccggacccgcggtacgaggcactgcgccagaccttccgcgacc
[0098] tcatggcgctgcccgacaccaaccgccacatcgccggcatgctctccggcttcgacgtcgcctacggcggcggc
[0099] gaccaccctctggtcggccgccggatgccggacgccgagctgatcaccgcggacgggccgcggaggatcagc
[0100] gattgcttcgccggggcccgcggtctgctgctgctccccgaacaggccccgaccgcctcgccgctggccgcctg
[0101] ggcggaccgcgtggacaccctgaccgtcaagtcgggcggcccggacgcggacaccgcccacctcgtccgccc
[0102] ggacggctacgtggcctgggccggcgaaccggcccgcaccgaggaactgcaccacgccgcgaccacctggtt
[0103] cggcgcggcggcctga2 is the ctcM base sequence 423
[0105] DNA
[0106] Streptomyces aureofaciens
[0107] Reverse
[0108] tcatgcctgcgcccccgccccgacgttgcgggccagcggcggagcctggcagtcggagtc
[0109] gatgccccaggagacgatccgctccggcgtgatccggatcagctcgtcgtcgacgtgcgg
[0110] caggatctccttgccgccggtcgccagcgcgacggcggtgccccggatctcgatcccgcg
[0111] gacgacccagcgctgcgcgtccacgatgtcgtccaccaccagtgacacccgcggatgccc
[0112] ctgcacgtggcggtacttgaggctgcgggccatgccgcgcccggtcacgtcgacggtgcc
[0113] gagctcggcgttgtagtggaagcccagcgggacgacgtgcggctgtccccggccgtccac
[0114] ggtggccaggcgggcgagcggctgcgaggccaggtaggcggcctctttcgcggtgaatgg
[0115] cat
[0116] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A genetically engineered recombinant strain for producing tetracycline, characterized in that: The recombinant strain is a starting strain in which the oxytetracycline synthesis-related genes C6, C5 hydroxylase and / or oxytetracycline synthesis-related genes C5a-C11a reductase are replaced in situ or ectopically; the starting strain is a strain capable of biosynthesizing oxytetracycline.
2. The genetically engineered recombinant strain for producing tetracycline according to claim 1, characterized in that: The recombinant strain is a starting strain in which the oxytetracycline synthesis-related genes C6 and C5 hydroxylase are replaced in situ or ectopically by C6 hydroxylase from the tetracycline biosynthesis pathway; and / or the oxytetracycline synthesis-related gene C5a-C11a reductase in the starting strain is replaced in situ or ectopically by C5a-C11a reductase from the tetracycline biosynthesis pathway.
3. The genetically engineered recombinant strain for producing tetracycline according to claim 1 or 2, characterized in that: The strain capable of biosynthesizing oxytetracycline is Streptomyces rimosus, S. rimosus LS-TI 18 (Russian), S. rimosus M4018 (Pfizer) or S. rimosus R6 (Zagreb); the strain having a tetracycline biosynthetic pathway is Streptomyces aureofaciens, Streptomyce viridofaciens, Streptomyces p. SF2575 or Dactylosporangium sp. SC14051.
4. The genetically engineered recombinant strain for producing tetracycline according to claim 1 or 2, characterized in that: The recombinant strain is a starting strain in which the oxytetracycline synthesis-related genes C6 and C5 hydroxylase are replaced in situ or ectopically by C6 hydroxylase from the tetracycline biosynthesis pathway; and / or the oxytetracycline synthesis-related gene C5a-C11a reductase in the starting strain is replaced in situ or ectopically by C5a-C11a reductase from the tetracycline biosynthesis pathway.
5. The genetically engineered recombinant strain for producing tetracycline according to claim 4, characterized in that: The base sequence of the C6 hydroxylase from the tetracycline biosynthetic pathway is shown by the bases in SEQ ID NO: 1; or a sequence having at least 30% amino acid sequence homology thereto.
6. The genetically engineered recombinant strain for producing tetracycline according to claim 4, characterized in that: The base sequence of the C5a-C11a reductase from the tetracycline biosynthetic pathway is shown by the bases in SEQ ID NO: 2; or a sequence having at least 30% amino acid sequence homology thereto.
7. A method for constructing a genetically engineered recombinant strain for producing tetracycline according to claim 1, characterized in that: By utilizing DNA homologous recombination, the C6 and C5 hydroxylases in a strain capable of biosynthesizing oxytetracycline are replaced in situ or ectopically, thereby obtaining a recombinant strain that produces tetracycline.
8. The method for constructing a genetically engineered recombinant strain for producing tetracycline according to claim 7, characterized in that: DNA homologous recombination is used to replace the functional genes ctcM and / or ctcN in the tetracycline biosynthesis gene cluster in situ or ectopically with the functional genes oxyR and / or oxyS in the oxytetracycline biosynthesis gene cluster in a strain having oxytetracycline biosynthesis, thereby obtaining a recombinant strain that produces tetracycline.
9. Use of the genetically engineered recombinant strain for producing tetracycline according to claim 1, characterized in that: The recombinant strain is used in producing tetracycline or its analogs.
10. A method for producing tetracycline or its analogs, characterized in that: The recombinant strain of claim 1 is shaken and cultured at 30-35° C., the fermentation broth is collected, and the broth is purified to produce tetracycline or its analogs.
